CA2374402A1 - Biosynthesis of foreign proteins using transformed microalgae - Google Patents
Biosynthesis of foreign proteins using transformed microalgae Download PDFInfo
- Publication number
- CA2374402A1 CA2374402A1 CA002374402A CA2374402A CA2374402A1 CA 2374402 A1 CA2374402 A1 CA 2374402A1 CA 002374402 A CA002374402 A CA 002374402A CA 2374402 A CA2374402 A CA 2374402A CA 2374402 A1 CA2374402 A1 CA 2374402A1
- Authority
- CA
- Canada
- Prior art keywords
- microalgae
- protein
- gene
- transformed
- chlorella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 80
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 51
- 230000015572 biosynthetic process Effects 0.000 title abstract description 9
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 25
- 210000001938 protoplast Anatomy 0.000 claims abstract description 20
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 claims abstract description 16
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108010035235 Phleomycins Proteins 0.000 claims abstract description 16
- 101150038738 ble gene Proteins 0.000 claims abstract description 12
- 239000003550 marker Substances 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 20
- 241000251468 Actinopterygii Species 0.000 claims description 17
- 241000269908 Platichthys flesus Species 0.000 claims description 15
- 108010051696 Growth Hormone Proteins 0.000 claims description 12
- 239000000122 growth hormone Substances 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 7
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 241000195585 Chlamydomonas Species 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000003570 biosynthesizing effect Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000701489 Cauliflower mosaic virus Species 0.000 claims description 3
- 241000611184 Amphora Species 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 241000199914 Dinophyceae Species 0.000 claims description 2
- 241000195634 Dunaliella Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000192701 Microcystis Species 0.000 claims description 2
- 241000196305 Nannochloris Species 0.000 claims description 2
- 241000224474 Nannochloropsis Species 0.000 claims description 2
- 241000502321 Navicula Species 0.000 claims description 2
- 241000180701 Nitzschia <flatworm> Species 0.000 claims description 2
- 241000192497 Oscillatoria Species 0.000 claims description 2
- 241000206731 Phaeodactylum Species 0.000 claims description 2
- 101150111829 RBCS2 gene Proteins 0.000 claims description 2
- 241000206733 Skeletonema Species 0.000 claims description 2
- 241000196321 Tetraselmis Species 0.000 claims description 2
- 241001491691 Thalassiosira Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 108010084455 Zeocin Proteins 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 235000012162 pavlova Nutrition 0.000 claims description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 2
- 239000013535 sea water Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- 108700003774 talisomycin Proteins 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 241001038158 Pavlovaceae Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 241000195615 Volvox Species 0.000 claims 1
- 150000007854 aminals Chemical class 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 239000013505 freshwater Substances 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 abstract description 4
- 241000195648 Pseudochlorella pringsheimii Species 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 230000009466 transformation Effects 0.000 description 13
- 102100038803 Somatotropin Human genes 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000001262 western blot Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 241000238426 Anostraca Species 0.000 description 4
- 241000700104 Brachionus plicatilis Species 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 108090000913 Nitrate Reductases Proteins 0.000 description 4
- 241000700141 Rotifera Species 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000269979 Paralichthys olivaceus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 2
- 241000238582 Artemia Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 241000195654 Chlorella sorokiniana Species 0.000 description 2
- 240000009108 Chlorella vulgaris Species 0.000 description 2
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 101100033187 Chlamydomonas reinhardtii RBCS2 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241001147476 Cyclotella Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241001646657 Detonula confervacea Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000133262 Nauplius Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000206766 Pavlova Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000203615 Streptoalloteichus Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 101150003560 trfA gene Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G33/00—Cultivation of seaweed or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Farming Of Fish And Shellfish (AREA)
- Fodder In General (AREA)
Abstract
The present invention relates to an economical method for biosynthesis of intended foreign proteins using transformed microalgae, that is to say, it relates to a method of using transformed microalgae as a bioreactor where economical biosynthesis of foreign protein is possible by transforming protoplast of microalgae such as Chlorella ellipsoideawith DNA vector containing intended foreign protein gene and then culturing it in a large scale. In particular, Sh ble gene, which is resistant to phleomycin, is used as a selection marker in the present invention.
Description
BIOSYNTHESIS OF FOREIGN PROTEINS USING
TRANSFORMED MICROALGAE
FIELD OF THE INVENTION
1. FILED OF THE INVENTION
The present invention relates to a method for biosynthesis of foreign protein using transformed microalgae. More particularly, it relates to a method for biosynthesis of foreign proteins by transforming microalgae protoplasts with DNA
vector containing intended foreign protein gene, and then culturing it in a large scale.
TRANSFORMED MICROALGAE
FIELD OF THE INVENTION
1. FILED OF THE INVENTION
The present invention relates to a method for biosynthesis of foreign protein using transformed microalgae. More particularly, it relates to a method for biosynthesis of foreign proteins by transforming microalgae protoplasts with DNA
vector containing intended foreign protein gene, and then culturing it in a large scale.
2. DESCRIPTION OF THE PRIOR ARTS
Escherichia coli is the most widely used heterologous expression system, but the bacterium has some limitations including; i) poor or no expression of certain proteins, ii) some recombinant proteins lack biological activity, iii) some recombinant proteins are toxic to Escherichia coli, and iv) some recombinant proteins form insoluble inclusion bodies. Similar problems can occur with yeast expression systems. Cultured mammalian and insect cells have been used to solve these problems, but these systems can be expensive because of the cost of media, 2o equipment and requirement for extensive purification procedures.
Therefore, the present inventors made an investigation on chlorella transformation as a new heterologous overexpression system, which could substitute for Escherichia coli, to solve the above-described problems.
As a result thereof, we have found that microalgae expression system was more economical than cell culture or animal or plant expression system because the microalgae had simpler metabolic pathway than those of animals or plants had and could be cultured in a large scale using an aquarium with light and carbon dioxide.
Moreover, the fact that microalgae has post-translational modification process unlike Escherichia coli indicates that the biological activity of foreign protein expressed in microalgae should be more similar to that of naturally occurnng protein. Under this circumstance, we intended to develop microalgae overexpression system for producing foreign proteins.
There had been attempts to transform the Chlorella species, one of 1o microalgae. Jarvis and Brown described the transient expression of luciferase in protoplasts of Chlorella ellipsoidea (Jarvis, E. E., and Brown, L. M. 1991.
Transient expression of firefly luciferase in protoplasts of the green alga Chlorella ellipsoidea, Current Genetics 19, 317-321) and Dawson et al. found that nitrate reductase-deficient mutants of Chlorella sorokiniana could be rescued by transforming them with nitrate reductase gene isolated from Chlorella vulgaris(Dawson, H. N., Burlingame, R., and Cannons, A. C. 1997. Stable transformation of Chlorella:
Rescue of nitrate reductase-deficient mutants with the nitrate reductase gene.
Current Microbiology 35, 356-362). However, these experiments described only transient expression or expression of protein genes originated from chlorella species.
Therefore, the present inventors made investigations on a method for biosynthesizing foreign protein by transforming protoplasts of microalgae with a vector DNA containing the genes originated from organisms other than microalgae and then culturing them in a large scale. As a result thereof, we found out that objects described above could be reached with this method.
Escherichia coli is the most widely used heterologous expression system, but the bacterium has some limitations including; i) poor or no expression of certain proteins, ii) some recombinant proteins lack biological activity, iii) some recombinant proteins are toxic to Escherichia coli, and iv) some recombinant proteins form insoluble inclusion bodies. Similar problems can occur with yeast expression systems. Cultured mammalian and insect cells have been used to solve these problems, but these systems can be expensive because of the cost of media, 2o equipment and requirement for extensive purification procedures.
Therefore, the present inventors made an investigation on chlorella transformation as a new heterologous overexpression system, which could substitute for Escherichia coli, to solve the above-described problems.
As a result thereof, we have found that microalgae expression system was more economical than cell culture or animal or plant expression system because the microalgae had simpler metabolic pathway than those of animals or plants had and could be cultured in a large scale using an aquarium with light and carbon dioxide.
Moreover, the fact that microalgae has post-translational modification process unlike Escherichia coli indicates that the biological activity of foreign protein expressed in microalgae should be more similar to that of naturally occurnng protein. Under this circumstance, we intended to develop microalgae overexpression system for producing foreign proteins.
There had been attempts to transform the Chlorella species, one of 1o microalgae. Jarvis and Brown described the transient expression of luciferase in protoplasts of Chlorella ellipsoidea (Jarvis, E. E., and Brown, L. M. 1991.
Transient expression of firefly luciferase in protoplasts of the green alga Chlorella ellipsoidea, Current Genetics 19, 317-321) and Dawson et al. found that nitrate reductase-deficient mutants of Chlorella sorokiniana could be rescued by transforming them with nitrate reductase gene isolated from Chlorella vulgaris(Dawson, H. N., Burlingame, R., and Cannons, A. C. 1997. Stable transformation of Chlorella:
Rescue of nitrate reductase-deficient mutants with the nitrate reductase gene.
Current Microbiology 35, 356-362). However, these experiments described only transient expression or expression of protein genes originated from chlorella species.
Therefore, the present inventors made investigations on a method for biosynthesizing foreign protein by transforming protoplasts of microalgae with a vector DNA containing the genes originated from organisms other than microalgae and then culturing them in a large scale. As a result thereof, we found out that objects described above could be reached with this method.
SUMMARY OF THE INVENTION
The object of present invention is to provide a method for the stable expression of a foreign protein in a microalgae overexpression system.
To achieve the above object, the method of the present invention is characterized in that which comprises the steps of; (i) obtaining protoplast of microalgae; (ii) preparing a vector containing genes coding desired proteins, said genes originated from organisms other than microalgae; (iii) introducing the vector into the protoplast to give transformed protoplast and (iv) culturing the transformed microalgae to produce the desired protein.
to Also, the method of the present invention could further comprise another step of selecting transformed cells with antibiotics between step (iii) and step (iv) other than the above steps.
The above and other objects, features and application of the present invention will be apparent to those of ordinary skill by the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows photographs of Chlorella ellipsoidea cells stained with calcofluor white before (a) and after (b) enzyme treatment for cell wall removal observed by fluorescent microscope.
Figure 2 shows a photograph of expression of GFP in transformed Chlorella ellipsoidea observed by fluorescent microscope.
Figure 3 shows a schematic diagram of the transformation vector pCTV
Figure 4 shows the growth of transformed and non-transformed Chlorella ellipsoidea cultured in medium containing or not containing phleomycin.
Figure 5 shows the results of PCR amplification and Southern blot analysis of flounder growth hormone(hereinafter fGH) gene and Sh ble gene inserted into genomic DNA of transformed Chlorella ellipsoidea.
In figure 5, panel A shows the result of PCR amplification and Southern blot analysis for fGH and panel B shows the result of PCR amplification and Southern blot analysis of Sh ble; lane 1 shows molecular weight size marker and lane 2 shows transformed Chlorella ellipsoidea and lane 3 shows non-transformed Chlorella ellipsoidea and lane 4 shows fGH and Sh ble gene fragments digested from pBluescript SK+.
Figure 6 shows the result of Western blot analysis of fGH expressed in tranformed Chlorella ellipsoidea. In figure 6, 1 ane 1 shows molecular weight size marker and lane 2 shows the Glutathione-S-transferase(hereinafter, GST)-fGH
fusion protein used for production of antibody and lane 3 shows the total protein isolated from non-transformed Chlorella ellipsoidea and lane 4 shows the total protein isolated from transformed Chlorella ellipsoidea.
Figure 7 shows the result of Western blot analysis showing the amount of fGH expressed in transformed Chlorella ellipsoidea. In figure 7, lane M shows molecular weight size marker and lane 1 & 2 show the 10~.g of GST-fGH fusion protein and lane 3 & 4 show the fGH isolated from lOml transformed Chlorella ellipsoidea and lane 5 & 6 show the 10~g of GST protein.
Figure 8 shows the results of Western blot analysis showing fGH
accumulated on Brachionus plicatilis and Anemia naupilus, both of which were fed with Chlorella ellipsoidea transformed with fGH. In figure 8, lane 1~4 show 5 PCT/KIt00/00233 Brachionus plicatilis 30, 60, 90 and 120 minutes, respectively after feeding with transformed Chlorella ellipsoidea and lane 6~8 show Artemia naupilus 30, 60 and 90 minutes, respectively after feeding with transformed Chlorella ellipsoidea.
Figure 9 shows the growth promotion of flounder by Chlorella ellipsoidea 5 transformed with fGH. In figure 9, open bars indicate the growth promotion by transformed Chlorella ellipsoidea, and filled bars indicate the growth promotion by non-transformed Chlorella ellipsoidea, and vertical line indicates standard deviation, and lower cases indicate significant differences (p<0.05).
Figure 10 shows the growth promotion of flounder fries after 30 days to feeding of Brachionus plicatilis and Artemia naupilus that had been fed for 1 hour with Chlorella ellipsoidea transformed with fGH.
DETAILED EXPLANATION OF THE INVENTION
Throughout the specification and claims, the term of foreign protein is used to mean any protein originated from organisms different from host microalgae, and it includes its active fragments, variants, and analogues as long as they retain its original biological activity. The term of "foreign gene" is used to indicate any nucleic acid sequence, regardless of its source(natural or synthetic), coding the foreign protein as defined above, and may include, DNA, RNA, cDNA or their 2o variants resulting form base deletion, substitution or insertion, as long as they still code for the foreign protein having its biological activity.
Chlorella ellipsoidea is an attractive organism for the production of complex proteins because of its eukaryotic characteristics and low cost for large-scale culture.
The inventors report the first functional expression of a foreign protein, the flounder growth hormone(fGH) in Chlorella ellipsoidea, and the growth promotion of fish by feeding them this transformed chlorella. Protoplasts of Chlorella ellipsoidea were transformed with a vector containing the fGH gene under the control of the cauliflower mosaic virus 35S promoter and the phleomycin resistance Sh ble gene under the control of the Chlamydomonas RBCS2 gene promoter. PCR
amplification and Southern blot analysis of the fGH and Sh ble genes from chromosomal DNA isolated from the transformants confirmed stable integration of introduced DNA. Western blot analysis indicated that the fGH protein was expressed in the transformed chlorella. The introduced DNA and the expressed 1o fGH were detected after seven successive transfers in media devoid of phleomycin.
The transformed chlorella cells were first fed to zooplanktons to remove the cellulose cell wall, and then the planktons were fed to flounder fries. These fish showed a 25% increase in total length and width after 30 days of feeding when compared to control fish. These results indicate that Chlorella ellipsoidea can be used to produce valuable proteins at low cost.
In the present invention, the green fluorescence from chlorella transformed with the GFP gene and the phleomycin resistance of chlorella transformed with Sh ble gene indicate the functional expression of these proteins. The biological activity of the recombinant fGH was confirmed by feeding flounder fry. Thus, in the 2o present invention, it was confirmed that the microalgae transformed with flounder growth hormone gene could express the hormone in a biologically active form.
Therefore, it's possible to produce valuable proteins for medicine and industry from transformed microalgae. In particular, microalgae could be produced with simple equipment and low cost, and a method of isolation and purification of expressed proteins therefrom is also simple, so that the cost of producing protein could be significantly reduced.
Further, this invention describes the successful use of the Sh ble gene as a selectable marker for Chlorella ellipsoidea transformation, the first demonstration of stable gene integration and expression of a biologically active foreign protein in the transformed Chlorella ellipsoidea. The results indicate that Chlorella ellipsoidea can be used to produce proteins of scientific or pharmacological use.
The microalgae used in the present invention are not particularly limited but the technique can be applied to other algae including Chlorella from sea and fresh to water such as Chlorella ellipsoidea, Chlorella sorokiniana and Chlorella vulgaris, Chlamydomonas, I~olvox, Cheatoceros, Phaeodactylum, Skeletonema, Navicula, Caloneise, Nitzschia, Thalassiosira, Amphora, Nannochloris, Nannochloropsis, Tetraselmis, Dunaliella, Spirulina, Microcystis, Oscillatoria, Tricodesminus, Isochryosis, Pavlova, Dinophyceae and the like.
The foreign protein gene used in the present invention is the flounder growth hormone gene. However, other genes originated from bacteria, fungi, virus, animals, plants or fishes could be used for overexpression by using the present invention.
And, vector production, cloning, transformation of host by vector, selection 2o and culture of transformant, and the recovering process of the desired protein after culture are known to those of skilled in the art.
The following examples are provided to illustrate the present invention, which should not be construed to limit the scope of the present invention.
The object of present invention is to provide a method for the stable expression of a foreign protein in a microalgae overexpression system.
To achieve the above object, the method of the present invention is characterized in that which comprises the steps of; (i) obtaining protoplast of microalgae; (ii) preparing a vector containing genes coding desired proteins, said genes originated from organisms other than microalgae; (iii) introducing the vector into the protoplast to give transformed protoplast and (iv) culturing the transformed microalgae to produce the desired protein.
to Also, the method of the present invention could further comprise another step of selecting transformed cells with antibiotics between step (iii) and step (iv) other than the above steps.
The above and other objects, features and application of the present invention will be apparent to those of ordinary skill by the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows photographs of Chlorella ellipsoidea cells stained with calcofluor white before (a) and after (b) enzyme treatment for cell wall removal observed by fluorescent microscope.
Figure 2 shows a photograph of expression of GFP in transformed Chlorella ellipsoidea observed by fluorescent microscope.
Figure 3 shows a schematic diagram of the transformation vector pCTV
Figure 4 shows the growth of transformed and non-transformed Chlorella ellipsoidea cultured in medium containing or not containing phleomycin.
Figure 5 shows the results of PCR amplification and Southern blot analysis of flounder growth hormone(hereinafter fGH) gene and Sh ble gene inserted into genomic DNA of transformed Chlorella ellipsoidea.
In figure 5, panel A shows the result of PCR amplification and Southern blot analysis for fGH and panel B shows the result of PCR amplification and Southern blot analysis of Sh ble; lane 1 shows molecular weight size marker and lane 2 shows transformed Chlorella ellipsoidea and lane 3 shows non-transformed Chlorella ellipsoidea and lane 4 shows fGH and Sh ble gene fragments digested from pBluescript SK+.
Figure 6 shows the result of Western blot analysis of fGH expressed in tranformed Chlorella ellipsoidea. In figure 6, 1 ane 1 shows molecular weight size marker and lane 2 shows the Glutathione-S-transferase(hereinafter, GST)-fGH
fusion protein used for production of antibody and lane 3 shows the total protein isolated from non-transformed Chlorella ellipsoidea and lane 4 shows the total protein isolated from transformed Chlorella ellipsoidea.
Figure 7 shows the result of Western blot analysis showing the amount of fGH expressed in transformed Chlorella ellipsoidea. In figure 7, lane M shows molecular weight size marker and lane 1 & 2 show the 10~.g of GST-fGH fusion protein and lane 3 & 4 show the fGH isolated from lOml transformed Chlorella ellipsoidea and lane 5 & 6 show the 10~g of GST protein.
Figure 8 shows the results of Western blot analysis showing fGH
accumulated on Brachionus plicatilis and Anemia naupilus, both of which were fed with Chlorella ellipsoidea transformed with fGH. In figure 8, lane 1~4 show 5 PCT/KIt00/00233 Brachionus plicatilis 30, 60, 90 and 120 minutes, respectively after feeding with transformed Chlorella ellipsoidea and lane 6~8 show Artemia naupilus 30, 60 and 90 minutes, respectively after feeding with transformed Chlorella ellipsoidea.
Figure 9 shows the growth promotion of flounder by Chlorella ellipsoidea 5 transformed with fGH. In figure 9, open bars indicate the growth promotion by transformed Chlorella ellipsoidea, and filled bars indicate the growth promotion by non-transformed Chlorella ellipsoidea, and vertical line indicates standard deviation, and lower cases indicate significant differences (p<0.05).
Figure 10 shows the growth promotion of flounder fries after 30 days to feeding of Brachionus plicatilis and Artemia naupilus that had been fed for 1 hour with Chlorella ellipsoidea transformed with fGH.
DETAILED EXPLANATION OF THE INVENTION
Throughout the specification and claims, the term of foreign protein is used to mean any protein originated from organisms different from host microalgae, and it includes its active fragments, variants, and analogues as long as they retain its original biological activity. The term of "foreign gene" is used to indicate any nucleic acid sequence, regardless of its source(natural or synthetic), coding the foreign protein as defined above, and may include, DNA, RNA, cDNA or their 2o variants resulting form base deletion, substitution or insertion, as long as they still code for the foreign protein having its biological activity.
Chlorella ellipsoidea is an attractive organism for the production of complex proteins because of its eukaryotic characteristics and low cost for large-scale culture.
The inventors report the first functional expression of a foreign protein, the flounder growth hormone(fGH) in Chlorella ellipsoidea, and the growth promotion of fish by feeding them this transformed chlorella. Protoplasts of Chlorella ellipsoidea were transformed with a vector containing the fGH gene under the control of the cauliflower mosaic virus 35S promoter and the phleomycin resistance Sh ble gene under the control of the Chlamydomonas RBCS2 gene promoter. PCR
amplification and Southern blot analysis of the fGH and Sh ble genes from chromosomal DNA isolated from the transformants confirmed stable integration of introduced DNA. Western blot analysis indicated that the fGH protein was expressed in the transformed chlorella. The introduced DNA and the expressed 1o fGH were detected after seven successive transfers in media devoid of phleomycin.
The transformed chlorella cells were first fed to zooplanktons to remove the cellulose cell wall, and then the planktons were fed to flounder fries. These fish showed a 25% increase in total length and width after 30 days of feeding when compared to control fish. These results indicate that Chlorella ellipsoidea can be used to produce valuable proteins at low cost.
In the present invention, the green fluorescence from chlorella transformed with the GFP gene and the phleomycin resistance of chlorella transformed with Sh ble gene indicate the functional expression of these proteins. The biological activity of the recombinant fGH was confirmed by feeding flounder fry. Thus, in the 2o present invention, it was confirmed that the microalgae transformed with flounder growth hormone gene could express the hormone in a biologically active form.
Therefore, it's possible to produce valuable proteins for medicine and industry from transformed microalgae. In particular, microalgae could be produced with simple equipment and low cost, and a method of isolation and purification of expressed proteins therefrom is also simple, so that the cost of producing protein could be significantly reduced.
Further, this invention describes the successful use of the Sh ble gene as a selectable marker for Chlorella ellipsoidea transformation, the first demonstration of stable gene integration and expression of a biologically active foreign protein in the transformed Chlorella ellipsoidea. The results indicate that Chlorella ellipsoidea can be used to produce proteins of scientific or pharmacological use.
The microalgae used in the present invention are not particularly limited but the technique can be applied to other algae including Chlorella from sea and fresh to water such as Chlorella ellipsoidea, Chlorella sorokiniana and Chlorella vulgaris, Chlamydomonas, I~olvox, Cheatoceros, Phaeodactylum, Skeletonema, Navicula, Caloneise, Nitzschia, Thalassiosira, Amphora, Nannochloris, Nannochloropsis, Tetraselmis, Dunaliella, Spirulina, Microcystis, Oscillatoria, Tricodesminus, Isochryosis, Pavlova, Dinophyceae and the like.
The foreign protein gene used in the present invention is the flounder growth hormone gene. However, other genes originated from bacteria, fungi, virus, animals, plants or fishes could be used for overexpression by using the present invention.
And, vector production, cloning, transformation of host by vector, selection 2o and culture of transformant, and the recovering process of the desired protein after culture are known to those of skilled in the art.
The following examples are provided to illustrate the present invention, which should not be construed to limit the scope of the present invention.
[EXAMPLE 1] Culture and protoplast formation of Chlorella ellipsoidea Chlorella epillsoidea was obtained from the Korea Marine Microalgae Culture Center of Pukyong National University (Strain No. KMCC C-20). Cells were inoculated in fresh f/2 medium(Guillard, R. R. L., and Ryther, J. H. 1962.
Studies on marine planktonic diatoms. I. Cyclotella nana Hustedt and Detonula confervacea(Cleve) Gran. Can. J. Microbiol. 3, 229-239) containing SO ~.g/ml each of chloramphenicol and streptomycin at an initial concentration of 1 X 1 O6 cells/ml and cultured at 25°C, 18:6 hour photoperiod under a 3000 lux fluorescent lamp. Cells were harvested for protoplast formation 8-9 days after inoculation when the cell 1o count reached 1-2 x108 cells/ml. Cells (SOmI) were centrifuged for Sminutes at 1,SOOxg, washed once with 25mM phosphate buffer (pH 6.0), and suspended in Sml of phosphate buffer containing 0.6M sorbitol, 0.6M mannitol, 4% (w/v) cellulase(Calbiochem, USA), 2%(w/v) macerase(Calbiochem), and SO units pectinase(Sigma Chemicals, USA). The cell suspension was incubated at 25°C for 16 hours in the dark with gentle shaking.
Protoplast formation of Chlorella ellipsoidea was confirmed in two ways. In an osmo-stability test, the number of enzyme treated cells in distilled water decreased from 1.7 x 106 cells/ml to 1.0 x 105 cells/ml in 8 hours, whereas no change occurred in the number of untreated chlorella. This result was confirmed by calcofluor 2o white staining(Maeda, H., and Ishida, N. 1967. Specificity of binding of hexapyranosyl polysaccharides with fluorescent brightner. J. Biochem. 62, 276-278).
Over 80% of enzyme-treated cells were red in contrast to untreated cells that were blue when visualized by fluorescent microscope (see Fig. 1 ); these findings indicated complete removal of the cellulose component of the cell wall, to which calcofluor white binds.
[EXAMPLE 2] Preparation of pMinGFP and the Expression of GFP
As a first step to develop a chlorella transformation system, a small 5 kb binary vector was constructed from the plant transformation vector Binl9(Bevan, M.
1984.
Binary Agrobacterium vectors for plant transformation. Nucleic Acids Res. 12, 8711-8712). The new vector called pMIN, contains the oriV origin for replication in both E. coli and Agrobacterium, the npt II gene for kanamycin resistance, the trfA
gene for DNA replication, and the right and left border T-DNA elements for integration. The subsequent cloning of a DNA fragment containing the cauliflower mosaic virus 35S promoter to direct expression of the green fluorescent protein (GFP) produced a vector pMinGFP for use in higher plant and algae transformation.
Chlorella protoplasts were transformed with pMinGFP by polyethylene treatment and the expression of GFP was measured. After 7 days of culture in f/2 medium without selection for transformation, a small number of chlorella cells exhibited GFP fluorescence, whereas non-transformed chlorella cells did not (see Fig.
2).
[EXAMPLE 3] Cloning the fGH gene A flounder cDNA library was constructed with the Lambda ZAP-II cDNA synthesis kit (Stratagene, USA) using total mRNA isolated from the Japanese flounder pituitary gland. The titer of the amplified library was 3x109 pfu/ml and a 1~1 aliquot 2o was used for PCR amplification. The DNA fragment amplified with fGH-AN (5'-CGGGATCCCAGCCAATCACAGA-3') and fGH-AC (5'-CGGGCTACAGAATTC-3') primers was cloned into the pGEM-T vector (Promega, USA) for sequence confirmation. A BamHIlNdeI fragment was subcloned into the pGEX-3X vector (Amersham Pharmacia Biotech, USA) for glutathion-S-transferase-fGH (GST-fGH) fusion protein expression; this fusion protein was used for polyclonal antibody production.
[EXAMPLE 4] Preparation of pMinfGH
Growth hormone genes have been cloned from several fish species and their growth-5 enhancing effects have been observed in transgenic fish. The growth hormone gene (fGH) from the Japanese flounder, Paralichthys olivaceus, the major aquaculture fish in Korea, was used to transform chlorella. The fGH gene was cloned by PCR amplification of a flounder pituitary cDNA library, using the fGH-N
primer (5'-CGGGATCCGGTCAGTCCCTTATGCAGCCAATCACA-3') and fGH-1o C primer (5'-AAAAGCTCGAGCTCTTGGCGGAG-3') (Watahiki, M., Yamamoto, M., Yamakawa, M., Tanaka, M. & Nakashima, K. 1989. Conserved and uniques amino acid residues in the domains of the growth hormone: flounder growth hormone deduced from the cDNA sequence has the minimal size in the growth hormone prolactin gene family. J. Biol. Chem. 264, 312-316). Replacement of the GFP gene in pMinGFP vector by the 560 by PCR product resulted in vector pMinfGH.
[EXAMPLE 5] Preperation of pCTV
We used the Sh ble gene, originated from Streptoalloteichus hindustamus, which encodes a small protein (13.7kDa) that confers resistance to tallysomycin, 2o bleomycin, phleomycin, and zeomycin by binding to the antibiotics and inhibiting their DNA cleaving activities. To determine if Chlorella ellipsoidea was inhibited by phleomycin, the alga was cultured in f/2 medium containing different concentrations of phleomycin; Reduced growth occurred in media containing 0.1 or 0.5 ~ g/ml phleomycin, and the alga failed to grow in media containing more than 1 ~glml phleomycin. Thus, the Sh ble gene that confers resistance to phleomycin is suitable to select transformed chlorella The Sh ble coding region and upstream Chlamydomonas reinhardtii RBCS2 promoter were amplified from the ~plasmid pSP109(Lumbreras, V, Stevens, D. R., & Purton, S. 1998. Efficient foreign gene expression in Chlamydomonas reinhardtii mediated by an endogenous intron.
Plant J.
14, 441-447) with ble-N primer (5'-AAACTCGAGGGCGCGCCAGAAGGAGC-3') and ble-C primer (5'-AAACTCGAGAATTCGAGGTCGGTACC-3'). The 880 by PCR product was digested with Xho I and subcloned into pMinfGH to construct the chlorella transformation vector pCTV (see Fig. 3).
[EXAMPLE 6] Transformation of Chlorella ellipsoidea with pCTV vector Chlorella protoplasts( 1 x 1 Og) were centrifuged at 400xg for 5 minutes, resuspended in 5 ml of f/2 medium containing 0.6M sorbitol/mannitol, centrifuged at 400Xg for S
minutes, and resuspended in lml of 0.6 M sorbitol/mannitol solution containing O.OSM CaCl2. Then, 1 X 108 protoplasts in 0.4m1 were placed in a fresh microcentrifuge tube and S~g of pCTV vector was added with 25~g calf thymus DNA(Sigma Chemicals). After 15 minutes incubation at room temperature, 2001 of PNC[0.8 M NaCI, 0.05 M CaCl2, 40 % PEG 4000(Sigma Chemicals)] was added and mixed gently for 30 minutes at room temperature. Then, 0.6 ml f/2 medium supplemented with 0.6 M sorbitol/mannitol, 1 % yeast extract and 1 % glucose was 2o added, and the cells were incubated at 25°C for 12 hours in the dark for cell wall regeneration. The cells were transferred to fresh f/2 medium containing phleomycin (l~g/ml) and cultured as described above.
Detectable growth occurred by 5 days and the cell growth reached stationary phase by 15 days. In contrast, no detectable growth occurred in non-transformed protoplasts(see Fig. 4). The slow growth of the transformed chlorella cells was consistent with the preliminary transformation experiments with pMinGFP, where only a small percentage (2%) of the cells displayed green fluorescence. When the transformed chlorella cells in the stationary phase were transferred to fresh f/2 medium or f/2 medium containing phleomycin, no detectable growth differences occurred. Furthermore, the growth rates in the two media were similar to the growth of non-transformed chlorella in f/2 medium lacking phleomycin (see Fig.
4).
These results indicate that the introduced DNA has no effect on chlorella growth;
also the transformed cells did not exhibit any morphological changes.
to [EXAMPLE 7] Stable integration of introduced DNA
Stable integration of introduced DNA into chromosomal DNA is a prerequisite for use of chlorella as an expression system. PCR and Southern analyses were performed to determine if the introduced DNA was integrated into the chlorella chromosomal DNA.
(Al. DNA isolation.
Approximately 3x108 transformed cells were pelleted from 3 ml of culture, resuspended in 500 ~l of CTAB buffer[250m1: hexadecyltrimethylammonium bromide(CTAB) Sg, 1M Tris(pH 8.0) 25m1, NaCI 20.45g, EDTA 1.68g, (3-mercaptoethanol(2%)] and incubated at 65°C for 1 hour, and then extracted with an 2o equal volume of phenol/chloroform. The aqueous phase recovered after 5 minutes centrifugation at 3,OOOxg was extracted several times and chromosomal DNA was precipitated with. ethanol, pelleted and resuspended in 30 ~1 of TE buffer.
(B). PCR and Southern blot analysis.
fGH-N/fGH-C and ble-N/ble-C primer pairs were used to amplify the fGH gene and the Sh ble gene from isolated chromosomal DNA, respectively. 200ng of chromosomal DNA and 100pmole of each of the primers were added to 50 p1 reactants, and subjected to 30 cycles of 1 minute denaturation at 94°C, 30 seconds annealing at 54 or 57°C for the fGH and the Sh ble genes, respectively, 1 minute extension at 72°C followed by 5 minutes extension at 72°C.
Probes for Southern blot were synthesized using the DIG-DNA labeling kit (Boehringer Mannheim, Germany).
PCR products of the expected size were produced only with DNA isolated from transformed chlorella. These DNA fragments were identified by Southern analyses to with probes specific to the fGH or Sh ble genes(see Fig. 5). The stability of the integrated DNA was confirmed by PCR amplification of the two genes from the chromosomal DNA isolated from chlorella after seven serial transfers into medium lacking phleomycin.
[EXAMPLE 8] Expression of fGH in tranformed Chlorella ellipsoidea fGH expression was tested by Western analysis as described hereinafter.
Transformed Chlorella ellipsoidea was harvested from 3 ml of culture containing 10$ to 109 cells by centrifuging for 5 minutes at 17,000 x g. The cells were homogenized in liquid nitrogen, resuspended in 20 p1 of sample loading buffer[1mM
EDTA, 250mM Tris-Cl (pH 6.8), 4 % SDS, 2 % ~' - mercaptoethanol, 0.2 2o bromophenyl blue, 50 % glycerol], and boiled for 10 minutes. The sample was centrifuged for 10 minutes at 12,000 x g and the supernatant was electrophoresed on a 15 % SDS-PAGE. Also, protein extracts prepared from non-transformed chlorella were separated by SDS-PAGE. Western blot analysis was conducted by standard procedures. Protein extracts separated from tramsformed and non-transformed chlorella by SDS-PAGE were transferred onto nitrocellulose membranes. The final dilution of polyclonal antibody against fGH was 1:3,000 and alkaline phosphatase-conjugated anti-mouse IgG was used as the secondary antibody.
The 20kDa fGH was present in transformed chlorella but absent in non-transformed s cells (see Fig. 6).
One requirement for a successful expression system is that the foreign protein be produced at high level. The amount of fGH expressed in transformed chlorella was determined by an Enzyme Linked Immunosorbent Assay (ELISA) and Western blots with purified GST, GST-fGH fusion protein and extract from transformed chlorella to using polyclonal antibody against GST-fGH fusion protein(see Fig. 7). About 400ng of fGH was obtained from 1 X 10g stationary phase cells (400p g of total protein in lml culture). The yield is equivalent to 400~g fGH per litter of cultured chlorella assuming a final cell count of 1x10$ cells /ml. Considering the low cost of culture medium for the alga, this system could be used to produce eukaryotic proteins, 15 especially proteins of pharmaceutical importance.
[EXAMPLE 8] Biological activity test Although chlorella can not be directly fed to fish and crustacean larvae because of the high cellulose content in their cell walls, chlorella have been used to mass culture zooplanktons, which contain cellulase. Also it is known that fish can take 2o up proteins in feed by pinocytosis and there are reports of fish growth promotion by the oral administration of recombinant mammalian and fish growth hormone.
Thus, four day old flounder larvae were grouped into 1000 fish each in a 300 litter tank filled with 200 litter of sea water. Rotifers (Brachionus plicatilis) and brine shrimp (Anemia nauplius) were used to accumulate the growth hormone and to remove the cellulose from chlorella cell wall. Zooplanktons were starved for one day after hatching and provided with 3x108 cells/ml of transformed and non-transformed chlorella for one hour. Western analysis confirmed that the fGH in the alga accumulated in zooplankton bodies by 1 hour of feeding; after 1 hour fGH
was 5 degraded and disappeared 2 hours after feeding (see Fig. 8). The flounder larvae were fed once a day with the rotifers for 10 days and then with a mixture of the rotifers and the brine shrimp for 5 days, followed by 15 days feeding with the brine shrimp. The final counts of the rotifer and the brine shrimp were 10 and 5 individuals/ml, respectively. Four day old flounder fries were cultured for 30 days 10 with zooplanktons enriched for 1 hour with transformed and non-transformed chlorella. The lengths of the fish larvae were measured after 10 day feeding and both the length and width of the larvae were measured after 30 day feeding. Fifty randomly selected fish were measured from each of three replicates containing fish. As shown in Fig. 9, the length of the fish differed significantly after 10 days 15 and had a 25% increase in both length and after 30 days (see Fig 10).
Although preferred embodiments of the present invention have been described in detail herein above, it should be clearly understood that many variations and/or modifications of the basic inventive concepts herein taught which may appear 2o to those skilled in the art will still fall with in the spirit and scope of the present invention identified in the appended claims.
Studies on marine planktonic diatoms. I. Cyclotella nana Hustedt and Detonula confervacea(Cleve) Gran. Can. J. Microbiol. 3, 229-239) containing SO ~.g/ml each of chloramphenicol and streptomycin at an initial concentration of 1 X 1 O6 cells/ml and cultured at 25°C, 18:6 hour photoperiod under a 3000 lux fluorescent lamp. Cells were harvested for protoplast formation 8-9 days after inoculation when the cell 1o count reached 1-2 x108 cells/ml. Cells (SOmI) were centrifuged for Sminutes at 1,SOOxg, washed once with 25mM phosphate buffer (pH 6.0), and suspended in Sml of phosphate buffer containing 0.6M sorbitol, 0.6M mannitol, 4% (w/v) cellulase(Calbiochem, USA), 2%(w/v) macerase(Calbiochem), and SO units pectinase(Sigma Chemicals, USA). The cell suspension was incubated at 25°C for 16 hours in the dark with gentle shaking.
Protoplast formation of Chlorella ellipsoidea was confirmed in two ways. In an osmo-stability test, the number of enzyme treated cells in distilled water decreased from 1.7 x 106 cells/ml to 1.0 x 105 cells/ml in 8 hours, whereas no change occurred in the number of untreated chlorella. This result was confirmed by calcofluor 2o white staining(Maeda, H., and Ishida, N. 1967. Specificity of binding of hexapyranosyl polysaccharides with fluorescent brightner. J. Biochem. 62, 276-278).
Over 80% of enzyme-treated cells were red in contrast to untreated cells that were blue when visualized by fluorescent microscope (see Fig. 1 ); these findings indicated complete removal of the cellulose component of the cell wall, to which calcofluor white binds.
[EXAMPLE 2] Preparation of pMinGFP and the Expression of GFP
As a first step to develop a chlorella transformation system, a small 5 kb binary vector was constructed from the plant transformation vector Binl9(Bevan, M.
1984.
Binary Agrobacterium vectors for plant transformation. Nucleic Acids Res. 12, 8711-8712). The new vector called pMIN, contains the oriV origin for replication in both E. coli and Agrobacterium, the npt II gene for kanamycin resistance, the trfA
gene for DNA replication, and the right and left border T-DNA elements for integration. The subsequent cloning of a DNA fragment containing the cauliflower mosaic virus 35S promoter to direct expression of the green fluorescent protein (GFP) produced a vector pMinGFP for use in higher plant and algae transformation.
Chlorella protoplasts were transformed with pMinGFP by polyethylene treatment and the expression of GFP was measured. After 7 days of culture in f/2 medium without selection for transformation, a small number of chlorella cells exhibited GFP fluorescence, whereas non-transformed chlorella cells did not (see Fig.
2).
[EXAMPLE 3] Cloning the fGH gene A flounder cDNA library was constructed with the Lambda ZAP-II cDNA synthesis kit (Stratagene, USA) using total mRNA isolated from the Japanese flounder pituitary gland. The titer of the amplified library was 3x109 pfu/ml and a 1~1 aliquot 2o was used for PCR amplification. The DNA fragment amplified with fGH-AN (5'-CGGGATCCCAGCCAATCACAGA-3') and fGH-AC (5'-CGGGCTACAGAATTC-3') primers was cloned into the pGEM-T vector (Promega, USA) for sequence confirmation. A BamHIlNdeI fragment was subcloned into the pGEX-3X vector (Amersham Pharmacia Biotech, USA) for glutathion-S-transferase-fGH (GST-fGH) fusion protein expression; this fusion protein was used for polyclonal antibody production.
[EXAMPLE 4] Preparation of pMinfGH
Growth hormone genes have been cloned from several fish species and their growth-5 enhancing effects have been observed in transgenic fish. The growth hormone gene (fGH) from the Japanese flounder, Paralichthys olivaceus, the major aquaculture fish in Korea, was used to transform chlorella. The fGH gene was cloned by PCR amplification of a flounder pituitary cDNA library, using the fGH-N
primer (5'-CGGGATCCGGTCAGTCCCTTATGCAGCCAATCACA-3') and fGH-1o C primer (5'-AAAAGCTCGAGCTCTTGGCGGAG-3') (Watahiki, M., Yamamoto, M., Yamakawa, M., Tanaka, M. & Nakashima, K. 1989. Conserved and uniques amino acid residues in the domains of the growth hormone: flounder growth hormone deduced from the cDNA sequence has the minimal size in the growth hormone prolactin gene family. J. Biol. Chem. 264, 312-316). Replacement of the GFP gene in pMinGFP vector by the 560 by PCR product resulted in vector pMinfGH.
[EXAMPLE 5] Preperation of pCTV
We used the Sh ble gene, originated from Streptoalloteichus hindustamus, which encodes a small protein (13.7kDa) that confers resistance to tallysomycin, 2o bleomycin, phleomycin, and zeomycin by binding to the antibiotics and inhibiting their DNA cleaving activities. To determine if Chlorella ellipsoidea was inhibited by phleomycin, the alga was cultured in f/2 medium containing different concentrations of phleomycin; Reduced growth occurred in media containing 0.1 or 0.5 ~ g/ml phleomycin, and the alga failed to grow in media containing more than 1 ~glml phleomycin. Thus, the Sh ble gene that confers resistance to phleomycin is suitable to select transformed chlorella The Sh ble coding region and upstream Chlamydomonas reinhardtii RBCS2 promoter were amplified from the ~plasmid pSP109(Lumbreras, V, Stevens, D. R., & Purton, S. 1998. Efficient foreign gene expression in Chlamydomonas reinhardtii mediated by an endogenous intron.
Plant J.
14, 441-447) with ble-N primer (5'-AAACTCGAGGGCGCGCCAGAAGGAGC-3') and ble-C primer (5'-AAACTCGAGAATTCGAGGTCGGTACC-3'). The 880 by PCR product was digested with Xho I and subcloned into pMinfGH to construct the chlorella transformation vector pCTV (see Fig. 3).
[EXAMPLE 6] Transformation of Chlorella ellipsoidea with pCTV vector Chlorella protoplasts( 1 x 1 Og) were centrifuged at 400xg for 5 minutes, resuspended in 5 ml of f/2 medium containing 0.6M sorbitol/mannitol, centrifuged at 400Xg for S
minutes, and resuspended in lml of 0.6 M sorbitol/mannitol solution containing O.OSM CaCl2. Then, 1 X 108 protoplasts in 0.4m1 were placed in a fresh microcentrifuge tube and S~g of pCTV vector was added with 25~g calf thymus DNA(Sigma Chemicals). After 15 minutes incubation at room temperature, 2001 of PNC[0.8 M NaCI, 0.05 M CaCl2, 40 % PEG 4000(Sigma Chemicals)] was added and mixed gently for 30 minutes at room temperature. Then, 0.6 ml f/2 medium supplemented with 0.6 M sorbitol/mannitol, 1 % yeast extract and 1 % glucose was 2o added, and the cells were incubated at 25°C for 12 hours in the dark for cell wall regeneration. The cells were transferred to fresh f/2 medium containing phleomycin (l~g/ml) and cultured as described above.
Detectable growth occurred by 5 days and the cell growth reached stationary phase by 15 days. In contrast, no detectable growth occurred in non-transformed protoplasts(see Fig. 4). The slow growth of the transformed chlorella cells was consistent with the preliminary transformation experiments with pMinGFP, where only a small percentage (2%) of the cells displayed green fluorescence. When the transformed chlorella cells in the stationary phase were transferred to fresh f/2 medium or f/2 medium containing phleomycin, no detectable growth differences occurred. Furthermore, the growth rates in the two media were similar to the growth of non-transformed chlorella in f/2 medium lacking phleomycin (see Fig.
4).
These results indicate that the introduced DNA has no effect on chlorella growth;
also the transformed cells did not exhibit any morphological changes.
to [EXAMPLE 7] Stable integration of introduced DNA
Stable integration of introduced DNA into chromosomal DNA is a prerequisite for use of chlorella as an expression system. PCR and Southern analyses were performed to determine if the introduced DNA was integrated into the chlorella chromosomal DNA.
(Al. DNA isolation.
Approximately 3x108 transformed cells were pelleted from 3 ml of culture, resuspended in 500 ~l of CTAB buffer[250m1: hexadecyltrimethylammonium bromide(CTAB) Sg, 1M Tris(pH 8.0) 25m1, NaCI 20.45g, EDTA 1.68g, (3-mercaptoethanol(2%)] and incubated at 65°C for 1 hour, and then extracted with an 2o equal volume of phenol/chloroform. The aqueous phase recovered after 5 minutes centrifugation at 3,OOOxg was extracted several times and chromosomal DNA was precipitated with. ethanol, pelleted and resuspended in 30 ~1 of TE buffer.
(B). PCR and Southern blot analysis.
fGH-N/fGH-C and ble-N/ble-C primer pairs were used to amplify the fGH gene and the Sh ble gene from isolated chromosomal DNA, respectively. 200ng of chromosomal DNA and 100pmole of each of the primers were added to 50 p1 reactants, and subjected to 30 cycles of 1 minute denaturation at 94°C, 30 seconds annealing at 54 or 57°C for the fGH and the Sh ble genes, respectively, 1 minute extension at 72°C followed by 5 minutes extension at 72°C.
Probes for Southern blot were synthesized using the DIG-DNA labeling kit (Boehringer Mannheim, Germany).
PCR products of the expected size were produced only with DNA isolated from transformed chlorella. These DNA fragments were identified by Southern analyses to with probes specific to the fGH or Sh ble genes(see Fig. 5). The stability of the integrated DNA was confirmed by PCR amplification of the two genes from the chromosomal DNA isolated from chlorella after seven serial transfers into medium lacking phleomycin.
[EXAMPLE 8] Expression of fGH in tranformed Chlorella ellipsoidea fGH expression was tested by Western analysis as described hereinafter.
Transformed Chlorella ellipsoidea was harvested from 3 ml of culture containing 10$ to 109 cells by centrifuging for 5 minutes at 17,000 x g. The cells were homogenized in liquid nitrogen, resuspended in 20 p1 of sample loading buffer[1mM
EDTA, 250mM Tris-Cl (pH 6.8), 4 % SDS, 2 % ~' - mercaptoethanol, 0.2 2o bromophenyl blue, 50 % glycerol], and boiled for 10 minutes. The sample was centrifuged for 10 minutes at 12,000 x g and the supernatant was electrophoresed on a 15 % SDS-PAGE. Also, protein extracts prepared from non-transformed chlorella were separated by SDS-PAGE. Western blot analysis was conducted by standard procedures. Protein extracts separated from tramsformed and non-transformed chlorella by SDS-PAGE were transferred onto nitrocellulose membranes. The final dilution of polyclonal antibody against fGH was 1:3,000 and alkaline phosphatase-conjugated anti-mouse IgG was used as the secondary antibody.
The 20kDa fGH was present in transformed chlorella but absent in non-transformed s cells (see Fig. 6).
One requirement for a successful expression system is that the foreign protein be produced at high level. The amount of fGH expressed in transformed chlorella was determined by an Enzyme Linked Immunosorbent Assay (ELISA) and Western blots with purified GST, GST-fGH fusion protein and extract from transformed chlorella to using polyclonal antibody against GST-fGH fusion protein(see Fig. 7). About 400ng of fGH was obtained from 1 X 10g stationary phase cells (400p g of total protein in lml culture). The yield is equivalent to 400~g fGH per litter of cultured chlorella assuming a final cell count of 1x10$ cells /ml. Considering the low cost of culture medium for the alga, this system could be used to produce eukaryotic proteins, 15 especially proteins of pharmaceutical importance.
[EXAMPLE 8] Biological activity test Although chlorella can not be directly fed to fish and crustacean larvae because of the high cellulose content in their cell walls, chlorella have been used to mass culture zooplanktons, which contain cellulase. Also it is known that fish can take 2o up proteins in feed by pinocytosis and there are reports of fish growth promotion by the oral administration of recombinant mammalian and fish growth hormone.
Thus, four day old flounder larvae were grouped into 1000 fish each in a 300 litter tank filled with 200 litter of sea water. Rotifers (Brachionus plicatilis) and brine shrimp (Anemia nauplius) were used to accumulate the growth hormone and to remove the cellulose from chlorella cell wall. Zooplanktons were starved for one day after hatching and provided with 3x108 cells/ml of transformed and non-transformed chlorella for one hour. Western analysis confirmed that the fGH in the alga accumulated in zooplankton bodies by 1 hour of feeding; after 1 hour fGH
was 5 degraded and disappeared 2 hours after feeding (see Fig. 8). The flounder larvae were fed once a day with the rotifers for 10 days and then with a mixture of the rotifers and the brine shrimp for 5 days, followed by 15 days feeding with the brine shrimp. The final counts of the rotifer and the brine shrimp were 10 and 5 individuals/ml, respectively. Four day old flounder fries were cultured for 30 days 10 with zooplanktons enriched for 1 hour with transformed and non-transformed chlorella. The lengths of the fish larvae were measured after 10 day feeding and both the length and width of the larvae were measured after 30 day feeding. Fifty randomly selected fish were measured from each of three replicates containing fish. As shown in Fig. 9, the length of the fish differed significantly after 10 days 15 and had a 25% increase in both length and after 30 days (see Fig 10).
Although preferred embodiments of the present invention have been described in detail herein above, it should be clearly understood that many variations and/or modifications of the basic inventive concepts herein taught which may appear 2o to those skilled in the art will still fall with in the spirit and scope of the present invention identified in the appended claims.
Claims (14)
1. A method for biosynthesizing of a foreign desired protein in microalgae which comprises the steps of (i) obtaining protoplast of microalgae;
(ii) preparing a vector containing a gene coding for the foreign desired protein, said gene being originated from organisms other than microalgae;
(iii) introducing the vector into the protoplast to give transformed protoplast; and (iv) culturing the transformed microalgae to produce the desired protein.
(ii) preparing a vector containing a gene coding for the foreign desired protein, said gene being originated from organisms other than microalgae;
(iii) introducing the vector into the protoplast to give transformed protoplast; and (iv) culturing the transformed microalgae to produce the desired protein.
2. The method according to claim 1, further comprising the step, following the culturing step, of recovering the protein from the microalgae.
3. The method according to claim 1, wherein said method further comprises a step of selecting transformed cells with antibiotics between step(iii) and step(iv).
4. The method according to claim 1, wherein said method further comprises a step of egenerating cell walls of the transformed protoplast between step(iii) and step(iv).
5. The method according to claim 3, wherein said vector contains Sh ble gene as a selection marker for transformant and wherein the antibiotics are selected from the group consisting of phleomycin, tallysomycin, bleomycin, and zeomycin.
6. The method according to claim 1, wherein said vector contains promoter which is selected from the group consisting of cauliflower mosaic virus 35S promoter and the Chlamydomonas RBCS2 gene promoter.
7. The method according to claim 1, wherein said microalgae is one of Chlorella from sea and fresh water, Chlamydomonas, Volvox, Cheatoceros, Phaeodactylum, Skeletonema, Navicula, Caloneise, Nitzschia, Thalassiosira, Amphora, Nannochloris, Nannochloropsis, Tetraselmis, Dunaliella, Spirulina, Microcystis, Oscillatoria, Tricodesminus, Isochryosis, Pavlova or Dinophyceae.
8. The method according to claim 1, wherein said desired foreign protein is originated from bacteria, fungi, virus, animals, plants or fishes.
9. The method according to claim 8, wherein said desired foreign protein is flounder growth hormone.
10. A recombinant DNA vector for biosynthesizing a desired foreign proteine in microalgae, comprising a gene coding for the desired foreign protein and Sh ble gene as a selection marker for transformant.
11. A trasformed microalgae for biosynthesizing a desired foreign protein, wherein the genome thereof is integrated with the desired foreign gene and Sh ble gene.
12. The trasformed microalgae according to claim 11, wherein said microalgae can express the desired foreign protein and Sh ble protein.
13. A desired foreign protein produced by expression of the foreign desired gene in the trasformed microalgae according to claim 11 or 12.
14. A method for breeding the aminal with the microalgae according to claim 11 or the protein according to claim 13.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990019439A KR20000075076A (en) | 1999-05-28 | 1999-05-28 | A method for production of foreign protein using transformed microalgae |
KR1999/19439 | 1999-05-28 | ||
PCT/KR2000/000233 WO2000073455A1 (en) | 1999-05-28 | 2000-03-17 | Biosynthesis of foreign proteins using transformed microalgae |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2374402A1 true CA2374402A1 (en) | 2000-12-07 |
Family
ID=19588391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002374402A Abandoned CA2374402A1 (en) | 1999-05-28 | 2000-03-17 | Biosynthesis of foreign proteins using transformed microalgae |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1180145A1 (en) |
JP (1) | JP2003501031A (en) |
KR (2) | KR20000075076A (en) |
CN (1) | CN1354792A (en) |
AU (1) | AU3333900A (en) |
CA (1) | CA2374402A1 (en) |
WO (1) | WO2000073455A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583019A (en) | 1995-01-24 | 1996-12-10 | Omegatech Inc. | Method for production of arachidonic acid |
WO2001098335A2 (en) | 2000-06-20 | 2001-12-27 | Phycotransgenics, Llc | Transgenic algae for delivering antigens to an animal |
TWI324181B (en) * | 2001-04-16 | 2010-05-01 | Martek Biosciences Corp | Product and process for transformation of thraustochytriales microorganisms |
US6399118B1 (en) * | 2001-06-29 | 2002-06-04 | Fish Biotech Ltd. | Process for storing enriched nematodes |
BRPI0412282A (en) | 2003-07-02 | 2006-09-19 | Musc Found For Res Dev | specific and nonspecifically induced dsrna immunity in crustaceans and other invertebrates, and bioliberation vehicles for use in these |
CN100415869C (en) * | 2004-03-26 | 2008-09-03 | 中国科学院海洋研究所 | Application of receptor expression system with Bryopsis hypnoides protoplasmcoacervate as exogenous gene |
TWI356705B (en) * | 2007-10-25 | 2012-01-21 | Internat Chlorella Co Ltd | Extracts from chlorella sorokiniana |
EP2090648A1 (en) * | 2008-02-12 | 2009-08-19 | Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) | Production of glycosylated polypeptides in microalgae |
US20100183523A1 (en) | 2009-01-22 | 2010-07-22 | Wagner Richard E | Dental composition and method |
WO2010084969A1 (en) * | 2009-01-23 | 2010-07-29 | 国立大学法人高知大学 | Novel promoter for use in transformation of algae |
TWI504749B (en) | 2009-03-16 | 2015-10-21 | Dsm Ip Assets Bv | Protein production in microorganisms of the phylum labyrinthulomycota |
CN101736025A (en) * | 2009-12-25 | 2010-06-16 | 国家海洋局第一海洋研究所 | Electric shock transformation method for golden alga |
CN107746869A (en) * | 2009-12-28 | 2018-03-02 | 赛诺菲疫苗技术公司 | The production of heterologous polypeptide in microalgae, the extracellular body of microalgae, composition and its production and use |
CN102703326B (en) * | 2012-02-13 | 2014-02-19 | 青岛理工大学 | Plant height CO2Tolerance and fixed rate microalgae and breeding method thereof |
KR101480051B1 (en) * | 2012-05-02 | 2015-01-09 | 한국생명공학연구원 | Selective Marker of Transformant Using Mutant Gene Encoding Ribosomal Proteinof Microalgae Thraustochytrid |
WO2014133159A1 (en) * | 2013-02-28 | 2014-09-04 | 株式会社ユーグレナ | Method for introducing gene to euglena, and transformant therefrom |
JP2014193154A (en) * | 2013-02-28 | 2014-10-09 | Euglena Co Ltd | Transformant of euglena |
JP2014193153A (en) * | 2013-02-28 | 2014-10-09 | Euglena Co Ltd | Method for introducing gene into euglena |
KR101660805B1 (en) | 2014-05-28 | 2016-09-28 | 주식회사 바이오에프디엔씨 | Transformant transformed by Glut-1 gene and Methods for culturing the Same |
KR101606634B1 (en) | 2014-05-28 | 2016-03-28 | 주식회사 바이오에프디엔씨 | Mass Production Method of Mycosporine-like amino acid |
KR102013788B1 (en) | 2016-11-04 | 2019-08-23 | 한국과학기술연구원 | A vector for expressing hEGF or PTD-hEGF and microalgae transformed with the same |
CN106591186A (en) * | 2016-12-13 | 2017-04-26 | 北京林业大学 | Preparation method of spirulina platensis protoplasts |
CN109706081A (en) * | 2017-10-25 | 2019-05-03 | 国家海洋局第三海洋研究所 | A kind of chlorella method for preparing protoplast |
KR102388144B1 (en) * | 2020-08-06 | 2022-04-19 | 한국생명공학연구원 | Method for producing Nannochloropsis transformant producing mycosporine-like amino acids massively using gene from Pyropia yezoensis |
KR102699731B1 (en) * | 2021-06-18 | 2024-08-28 | 국립부경대학교 산학협력단 | Feed additive composition for preventing or improving WSS comprising transgenic microalgae expressing WSSV envelope protein as an active ingredient, and use thereof |
KR20230016452A (en) * | 2021-07-26 | 2023-02-02 | 그린미네랄 주식회사 | Biomineralization vector and transformant for transformation of Chlorella vulgaris |
JP2024529454A (en) * | 2021-07-26 | 2024-08-06 | グリーン ミネラル インコーポレイテッド | Vector system for transformation of Chlorella vulgaris and method for transformation of Chlorella vulgaris |
CN113699046A (en) * | 2021-08-10 | 2021-11-26 | 吴信忠 | Chlorella containing AIF1 cytokine antibody, and its preparation method and application |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0376583A (en) * | 1989-08-16 | 1991-04-02 | Hagiwara Yoshihide | Manifestation of human protein in blue-green algae |
US5804408A (en) * | 1991-03-13 | 1998-09-08 | Yoshihide Hagiwara | Expression of human SOD in blue green algae |
JPH0568572A (en) * | 1991-09-11 | 1993-03-23 | Agency Of Ind Science & Technol | Blue-green alga synechococcus capable of producing salmon growth hormone |
WO1998042748A1 (en) * | 1997-03-24 | 1998-10-01 | Hih.Biocenter Inc. | New synthetic polypeptide |
-
1999
- 1999-05-28 KR KR1019990019439A patent/KR20000075076A/en active Search and Examination
-
2000
- 2000-03-17 CA CA002374402A patent/CA2374402A1/en not_active Abandoned
- 2000-03-17 JP JP2001500767A patent/JP2003501031A/en active Pending
- 2000-03-17 WO PCT/KR2000/000233 patent/WO2000073455A1/en not_active Application Discontinuation
- 2000-03-17 CN CN00808116A patent/CN1354792A/en active Pending
- 2000-03-17 AU AU33339/00A patent/AU3333900A/en not_active Abandoned
- 2000-03-17 EP EP00911471A patent/EP1180145A1/en not_active Withdrawn
- 2000-03-17 KR KR10-2001-7003167A patent/KR100443843B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU3333900A (en) | 2000-12-18 |
JP2003501031A (en) | 2003-01-14 |
CN1354792A (en) | 2002-06-19 |
KR20010073152A (en) | 2001-07-31 |
WO2000073455A1 (en) | 2000-12-07 |
KR20000075076A (en) | 2000-12-15 |
EP1180145A1 (en) | 2002-02-20 |
KR100443843B1 (en) | 2004-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2374402A1 (en) | Biosynthesis of foreign proteins using transformed microalgae | |
Kim et al. | Stable integration and functional expression of flounder growth hormone gene in transformed microalga, Chlorella ellipsoidea | |
US11344590B2 (en) | Transgenic microalgae and use thereof for oral delivery of proteins | |
DE60130447T2 (en) | TROPHICAL CONVERSION OF OBLIGAT PHOTOTROPIC ALGAE BY METABOLIC MANIPULATION | |
JPH07502880A (en) | Stable transformation method of maize cells by electroporation | |
DD285367A5 (en) | REGENERATION OF GRAMINE PLANTS FROM THE POOIDEAE UNDERPATHING FROM PROTOPLASTS | |
CN106029091B (en) | Algal-based edible vaccines | |
CN110088284A (en) | The method of high-level thebaine opium poppy and its production | |
KR100190253B1 (en) | Method for the production of proteins in plant fluids | |
JPH06504439A (en) | Low temperature tolerant plants and their production method | |
DE69924005T2 (en) | TRANSGENIC PLANTS WITH CONDITIONAL LETHAL GEN | |
KR101661706B1 (en) | Method for producing lysophosphatidylethanolamine 18:1 from microorganisms | |
US20110014708A1 (en) | Nucleic acid for use in algae and use thereof | |
JP2003513632A (en) | Protein expression system of nonpathogenic kinetoplastidae | |
DE69823188T2 (en) | CLONING UPD GALACTOSEPIMERASE | |
KR102286087B1 (en) | Chlamydomonas mutants and use thereof | |
US7005561B2 (en) | Arabitol or ribitol as positive selectable markers | |
CN105693834B (en) | Application of the soybean protein GmVPS9a2 in regulation plant storage protein sorting | |
Bryant | At last: transgenic cereal plants from genetically engineered protoplasts | |
JP5688849B2 (en) | Transgenic goldfish | |
EP1637606A2 (en) | Triacylglycerol lipases | |
CA2416584A1 (en) | Methods for the controlled, automatic excision of heterologous dna from transgenic plants and dna-excising gene cassettes for use therein | |
KR20000024893A (en) | Process for producing transformed microalgae | |
CN117757838A (en) | Method for creating sweet corn germplasm and related biological materials thereof | |
TW201408774A (en) | Cloning and application of gene in Vernicia montana promoting the plant biomass |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |